Document and Entity Information
Document and Entity Information Document - shares | 3 Months Ended | |
Mar. 31, 2019 | Apr. 25, 2019 | |
Entity [Abstract] | ||
Entity Registrant Name | TRUPANION, INC. | |
Entity Central Index Key | 0001371285 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Trading Symbol | TRUP | |
Entity Common Stock, Shares Outstanding | 34,489,695 |
Consolidated Statement of Opera
Consolidated Statement of Operations - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Income Statement [Abstract] | ||
Revenue | $ 86,978 | $ 69,760 |
Cost of Revenue [Abstract] | ||
Veterinary invoice expense | 61,282 | 50,113 |
Other cost of revenue | 10,664 | 8,583 |
Gross profit | 15,032 | 11,064 |
Operating Expenses [Abstract] | ||
Technology and Development | 2,669 | 2,164 |
General and administrative | 5,419 | 4,458 |
Sales and marketing | 8,227 | 5,938 |
Total operating expenses | 16,315 | 12,560 |
Operating loss | (1,283) | (1,496) |
Interest expense | 317 | 219 |
Other income, net | (344) | (140) |
Income (Loss) before income taxes | (1,256) | (1,575) |
Income tax expense (benefit) | 40 | (95) |
Net loss | $ (1,296) | $ (1,480) |
Earnings Per Share, Basic and Diluted | $ (0.04) | $ (0.05) |
Weighted Average Number of Shares Outstanding, Basic and Diluted | 34,292,367 | 30,246,585 |
Consolidated Statement of Compr
Consolidated Statement of Comprehensive Income Statement - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Statement of Comprehensive Income [Abstract] | ||
Net loss | $ (1,296) | $ (1,480) |
Foreign currency translation adjustments | 189 | (190) |
Net unrealized gain (loss) on available-for-sale debt securities | 19 | (15) |
Other comprehensive income (loss), net of taxes | 208 | (205) |
Comprehensive Income (Loss) | $ (1,088) | $ (1,685) |
Consolidated Balance Sheet
Consolidated Balance Sheet - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Assets [Abstract] | ||
Cash and cash equivalents | $ 26,622 | $ 26,552 |
Short-term Investments | 61,648 | 54,559 |
Accounts and other receivables | 37,568 | 31,565 |
Prepaid expenses and other assets | 4,847 | 5,300 |
Total current assets | 130,685 | 117,976 |
Restricted Cash | 1,400 | 1,400 |
Long-Term Investments, at fair value | 3,701 | 3,554 |
Property and equipment, net | 69,365 | 69,803 |
Intangible assets, net | 7,839 | 8,071 |
Other Long-Term Assets | 8,315 | 6,706 |
Total assets | 221,305 | 207,510 |
Liabilities and Equity [Abstract] | ||
Accounts payable | 2,897 | 2,767 |
Accrued liabilities and other current liabilities | 12,059 | 11,347 |
Reserve for veterinary invoices | 17,175 | 16,062 |
Deferred Revenue | 38,594 | 33,027 |
Total current liabilities | 70,725 | 63,203 |
Long-term debt | 18,078 | 12,862 |
Deferred tax liabilities | 1,002 | 1,002 |
Other liabilities | 1,491 | 1,270 |
Total liabilities | 91,296 | 78,337 |
Common stock | 0 | 0 |
Preferred Stock | 0 | 0 |
Additional paid-in capital | 226,262 | 219,838 |
Accumulated other comprehensive loss | (545) | (753) |
Accumulated deficit | (85,007) | (83,711) |
Treasury stock, at cost | (10,701) | (6,201) |
Stockholders' Equity Attributable to Parent | 130,009 | 129,173 |
Total liabilities and stockholders' equity | $ 221,305 | $ 207,510 |
Consolidated Balance Sheet Cond
Consolidated Balance Sheet Condensed Consolidated Balance Sheet Parentheticals - $ / shares | Mar. 31, 2019 | Dec. 31, 2018 |
Common Stock, Par or Stated Value Per Share | $ 0.00001 | $ 0.00001 |
Common Stock, Shares Authorized | 100,000,000 | 100,000,000 |
Common Stock, Shares, Issued | 35,397,330 | 34,781,121 |
Common Stock, Shares, Outstanding | 34,467,465 | 34,025,136 |
Preferred Stock, Par or Stated Value Per Share | $ 0.00001 | $ 0.00001 |
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 |
Preferred Stock, Shares Issued | 0 | 0 |
Preferred Stock, Shares Outstanding | 0 | 0 |
Treasury Stock, Shares | 929,865 | 755,985 |
Consolidated Statement of Stock
Consolidated Statement of Stockholders' Equity Statement - USD ($) $ in Thousands | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Treasury Stock [Member] |
Common Stock, Shares, Outstanding | 30,121,496 | |||||
Stockholders' Equity Attributable to Parent | $ 48,434 | $ 0 | $ 134,511 | $ (82,784) | $ (92) | $ (3,201) |
Redemption of warrants | 201,315 | |||||
Settlement of warrant liabilities | 0 | 3,000 | (3,000) | |||
Stock Issued During Period, Shares, Share-based Compensation, Net of Tax Withholdings | 108,104 | |||||
Stock Issued During Period, Value, Share-based Compensation, Net of Tax Withholdings | 481 | 481 | ||||
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition | 1,017 | 1,017 | ||||
Other Comprehensive Income (Loss), Net of Tax | (205) | (205) | ||||
Net Income (Loss) Available to Common Stockholders, Basic | (1,480) | (1,480) | ||||
Common Stock, Shares, Outstanding | 30,430,915 | |||||
Stockholders' Equity Attributable to Parent | $ 48,247 | $ 0 | 139,009 | (84,264) | (297) | (6,201) |
Common Stock, Shares, Outstanding | 34,025,136 | |||||
Stockholders' Equity Attributable to Parent | $ 129,173 | $ 0 | 219,838 | (83,711) | (753) | (6,201) |
Redemption of warrants | 450,000 | 276,120 | ||||
Settlement of warrant liabilities | $ 0 | 4,500 | (4,500) | |||
Stock Issued During Period, Shares, Share-based Compensation, Net of Tax Withholdings | 166,209 | |||||
Stock Issued During Period, Value, Share-based Compensation, Net of Tax Withholdings | 507 | 507 | ||||
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition | 1,417 | 1,417 | ||||
Other Comprehensive Income (Loss), Net of Tax | 208 | 208 | ||||
Net Income (Loss) Available to Common Stockholders, Basic | $ (1,296) | (1,296) | ||||
Common Stock, Shares, Outstanding | 34,467,465 | 34,467,465 | ||||
Stockholders' Equity Attributable to Parent | $ 130,009 | $ 0 | $ 226,262 | $ (85,007) | $ (545) | $ (10,701) |
Consolidated Statement of Cash
Consolidated Statement of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Net Cash Provided by Operating Activities [Abstract] | ||
Net loss | $ (1,296) | $ (1,480) |
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] | ||
Depreciation and Amortization | 1,613 | 927 |
Stock-based compensation expense | 1,357 | 968 |
Other, Net | (3) | 23 |
Increase (Decrease) in Operating Assets [Abstract] | ||
Accounts and other receivables | 5,894 | 3,926 |
Prepaid expenses and other assets | (325) | 129 |
Accounts Payable, Accrued Liabilities, and Other Liabilities | 1,256 | 910 |
Claims Reserve | 1,078 | 743 |
Deferred revenue | 5,523 | 4,041 |
Net cash provided by operating activities | 3,959 | 2,077 |
Net Cash Provided by Investing Activities [Abstract] | ||
Payments to Acquire Investments | (17,350) | (7,140) |
Maturities of Investment Securities | 10,205 | 5,300 |
Purchases of property and equipment | (878) | (992) |
Payments for (Proceeds from) Other Investing Activities | (1,479) | 0 |
Net cash used in investing activities | (9,502) | (2,832) |
Net Cash Provided by Financing Activities [Abstract] | ||
Proceeds from exercise of stock options | 661 | 481 |
Payments Related to Tax Withholding for Share-based Compensation | (197) | 0 |
Proceeds from Debt, Net of Issuance Costs | 5,200 | 5,500 |
Proceeds from (Payments for) Other Financing Activities | (271) | (216) |
Net cash provided by financing activities | 5,393 | 5,765 |
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net | 220 | 70 |
Net Increase in Cash, Cash Equivalents, and Restricted Cash | 70 | 5,080 |
Cash, Cash Equivalents, and Restricted Cash at beginning of period | 27,952 | 26,306 |
Cash, Cash Equivalents, and Restricted Cash, End of Period | 28,022 | 31,386 |
Supplemental Cash Flow Information [Abstract] | ||
Redemption of Warrants Non-Cash; Common Stock | 4,500 | 3,000 |
Purchases of property and equipment included in accounts payable and accrued liabilities | $ 141 | $ 680 |
Nature of Operations and Summar
Nature of Operations and Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of Operations and Summary of Significant Accounting Policies | Nature of Operations and Significant Accounting Policies Description of Business and Basis of Presentation Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the Company) provides medical insurance for cats and dogs throughout the United States, Canada and Puerto Rico. The financial data as of December 31, 2018 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income (loss), stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on February 14, 2019 (the 2018 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2018 10-K. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2018 10-K for additional discussion of these estimates and assumptions. Recently Adopted Accounting Pronouncements The Company adopted Accounting Standards Update (ASU) No. 2016-02 Leases (Topic 842), as amended, using the modified retrospective approach under which the transition provisions were applied as of January 1, 2019. In addition, the Company elected the “package of practical expedients” under the transition guidance within the new standard to not reassess prior conclusions about lease identification, lease classification, and initial direct costs for existing lease contracts. The Company also elected the practical expedient to not separate lease and non-lease components, if any, for all lease contracts. Upon adoption of this standard, the Company recorded approximately $0.1 million right-of-use assets and lease liabilities for operating leases. They were classified as other long-term assets and other liabilities on the Company's consolidated balance sheets. The standard did not have a material impact on the Company's consolidated statements of operations, stockholders' equity, or cash flows. Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued an ASU amending the measurement of credit losses on financial instruments. The ASU requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within that reporting period, with early adoption permitted. The Company is currently in the process of evaluating the impact the adoption of this ASU will have on its consolidated financial statements. |
Net Loss per Share
Net Loss per Share | 3 Months Ended |
Mar. 31, 2019 | |
Earnings Per Share, Basic and Diluted [Abstract] | |
Earnings Per Share [Text Block] | Net Income (Loss) per Share Basic net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated using the weighted average number of shares of common stock plus, when dilutive, potential shares of common stock outstanding using the treasury-stock method. Potential shares of common stock outstanding include stock options, unvested restricted stock awards and restricted stock units, and warrants. The following potentially dilutive equity securities were not included in the diluted earnings per share of common stock calculation because they would have had an antidilutive effect: Three Months Ended March 31, 2019 2018 Stock options 2,513,946 3,878,716 Restricted stock awards and restricted stock units 716,319 546,638 Warrants 30,000 510,000 |
Investment Securities (Notes)
Investment Securities (Notes) | 3 Months Ended |
Mar. 31, 2019 | |
Investments [Abstract] | |
Investment [Text Block] | The amortized cost, gross unrealized holding gains and losses, and estimates of fair value of long-term and short-term investments by major security type and class of security were as follows as of March 31, 2019 and December 31, 2018 (in thousands): Amortized Gross Gross Fair As of March 31, 2019 Long-term investments: Foreign deposits $ 2,701 $ — $ — $ 2,701 Municipal bond 1,000 — — 1,000 $ 3,701 $ — $ — $ 3,701 Short-term investments: U.S. Treasury securities $ 6,660 $ — $ — $ 6,660 Certificates of deposit 438 1 — 439 U.S. government funds 54,550 — — 54,550 $ 61,648 $ 1 $ — $ 61,649 Amortized Gross Gross Fair As of December 31, 2018 Long-term investments: Foreign deposits $ 2,573 $ — $ — $ 2,573 Municipal bond 1,000 — (19 ) 981 $ 3,573 $ — $ (19 ) $ 3,554 Short-term investments: U.S. Treasury securities $ 6,645 $ — $ (3 ) $ 6,642 Certificates of deposit 437 — — 437 U.S. government funds 47,477 — — 47,477 $ 54,559 $ — $ (3 ) $ 54,556 Maturities of debt securities classified as available-for-sale were as follows (in thousands): As of March 31, 2019 Amortized Fair Available-for-sale: Due after one year through five years $ 3,701 $ 3,701 $ 3,701 $ 3,701 |
Investments [Text Block] | The amortized cost, gross unrealized holding gains and losses, and estimates of fair value of long-term and short-term investments by major security type and class of security were as follows as of March 31, 2019 and December 31, 2018 (in thousands): Amortized Gross Gross Fair As of March 31, 2019 Long-term investments: Foreign deposits $ 2,701 $ — $ — $ 2,701 Municipal bond 1,000 — — 1,000 $ 3,701 $ — $ — $ 3,701 Short-term investments: U.S. Treasury securities $ 6,660 $ — $ — $ 6,660 Certificates of deposit 438 1 — 439 U.S. government funds 54,550 — — 54,550 $ 61,648 $ 1 $ — $ 61,649 Amortized Gross Gross Fair As of December 31, 2018 Long-term investments: Foreign deposits $ 2,573 $ — $ — $ 2,573 Municipal bond 1,000 — (19 ) 981 $ 3,573 $ — $ (19 ) $ 3,554 Short-term investments: U.S. Treasury securities $ 6,645 $ — $ (3 ) $ 6,642 Certificates of deposit 437 — — 437 U.S. government funds 47,477 — — 47,477 $ 54,559 $ — $ (3 ) $ 54,556 |
Other Investments (Notes)
Other Investments (Notes) | 3 Months Ended |
Mar. 31, 2019 | |
Investments, All Other Investments [Abstract] | |
Investments and Other Noncurrent Assets [Text Block] | Other Investments Investment in Variable Interest Entity In July 2018, the Company purchased $3.0 million in preferred stock of a privately held corporation with a complementary business line. The Company does not have power over the activities that most significantly impact the economic performance of the variable interest entity and is, therefore, not the primary beneficiary. The Company's investment in preferred stock is accounted for as an available-for-sale debt security. Through January 2020, the Company has agreed to purchase an additional $4.0 million in preferred stock of the variable interest entity, contingent upon the exercise of this option by the variable interest entity. The Company has the option to purchase the variable interest entity on the fifth anniversary of the initial preferred stock purchase. Additionally, the Company has extended a $2.5 million revolving line of credit to the variable interest entity. The Company's investment and amounts loaned under the line of credit are recorded in other long-term assets on its consolidated balance sheet. Outstanding loan balance under the line of credit was $2.1 million and $0.6 million as of March 31, 2019 and December 31, 2018, respectively. Investment in Joint Venture In September 2018, the Company acquired a non-controlling equity interest in a joint venture, whereby it has committed to licensing certain intellectual property and contributing up to $2.2 million AUD upon the achievement of specific operational milestones over a period of at least four years from the agreement execution date. As of March 31, 2019, the Company has contributed $0.3 million |
Fair Value
Fair Value | 3 Months Ended |
Mar. 31, 2019 | |
Fair Value Disclosures [Abstract] | |
Fair Value Disclosures [Text Block] | Fair Value Investments The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands): As of March 31, 2019 Fair Value Level 1 Level 2 Level 3 Assets Restricted cash $ 1,400 $ 1,400 $ — $ — Money market funds 4,022 4,022 — — Fixed maturities: Foreign deposits 2,701 2,701 — — Municipal bond 1,000 — 1,000 — Investment in variable interest entity 3,000 — — 3,000 Total $ 12,123 $ 8,123 $ 1,000 $ 3,000 As of December 31, 2018 Fair Value Level 1 Level 2 Level 3 Assets Restricted cash $ 1,400 $ 1,400 $ — $ — Money market funds 2,010 2,010 — — Fixed maturities: Foreign deposits 2,573 2,573 — — Municipal bond 981 — 981 — Investment in variable interest entity 3,000 — — 3,000 Total $ 9,964 $ 5,983 $ 981 $ 3,000 The Company measures the fair value of restricted cash, money market funds, and foreign deposits based on quoted prices in active markets for identical assets. The fair value of the municipal bond is based on either recent trades in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. The estimated fair value of the Company's investment in the variable interest entity is a Level 3 measurement, and is based on market interest rates, the assessed creditworthiness of the entity, and the estimated fair value of the entity's common stock. As of March 31, 2019 , the Company estimates that the purchase price approximates the fair value. Short-term investments are carried at amortized cost and the fair value is disclosed in Note 3, Investments. The fair value of these investments is determined in the same manner as for available-for-sale securities and is considered a Level 1 measurement. Fair Value Disclosures The Company's other long-term assets balance included $4.5 million of notes receivable as of March 31, 2019 and $3.0 million of notes receivable as of December 31, 2018, recorded at its estimated collectible amount. The Company estimates that the carrying value of the note receivable approximates its fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy, and is based on market interest rates and the assessed creditworthiness of the third party. The Company estimates the fair value of its long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at March 31, 2019 and December 31, 2018 |
Debt
Debt | 3 Months Ended |
Mar. 31, 2019 | |
Debt Disclosure [Abstract] | |
Debt Disclosure [Text Block] | Debt The Company has a revolving line of credit of up to $50.0 million , maturing June 2021. The facility is secured by any and all interests in the Company's assets that are not otherwise restricted. Interest on the revolving line of credit is payable monthly at the greater of 4.5%, or 1.25% plus the prime rate ( 6.75% at March 31, 2019 ). The credit agreement includes other ancillary services and letters of credit of up to $4.5 million , and requires a deposit of restricted cash of $1.4 million . The credit agreement requires the Company to comply with various financial and non-financial covenants. As of March 31, 2019 , the Company was in compliance with all financial and non-financial covenants required by the credit agreement. Borrowings on the revolving line of credit are limited to the lesser of $50.0 million and the total amount of cash and securities held by the Company's insurance subsidiaries (American Pet Insurance Company and Wyndham Insurance Company (SAC) Limited Segregated Account AX). As of March 31, 2019 , available borrowing capacity on the line of credit was $31.4 million , with an outstanding balance of $0.4 million for ancillary services and letters of credit, and borrowings under the facility of $18.2 million , recorded net of financing fees of $0.1 million |
Commitment and Contingencies
Commitment and Contingencies | 3 Months Ended |
Mar. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | Commitments and Contingencies Certain state insurance regulators in the United States have contacted the Company regarding whether employees who had helped prospective members enroll by telephone in prior years were required to have an insurance license to conduct such telephone conversations. To date, the Company has resolved each of these matters in non-material amounts and believes it is compliant with the applicable regulations. The Company is currently engaged with a limited number of state insurance regulators to resolve this same legacy issue and believes it has adequately reserved for these matters. |
Claims Reserve
Claims Reserve | 3 Months Ended |
Mar. 31, 2019 | |
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] | |
Supplementary Insurance Information, for Insurance Companies Disclosure [Text Block] | Reserve for Veterinary Invoices The reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. The reserve estimate involves actuarial projections, and is based on management's assessment of facts and circumstances currently known, and assumptions about anticipated patterns. The reserve is made for each of the Company's segments, subscription and other business, and is continually refined as the Company receives and pays veterinary invoices. Changes in management's assumptions and estimates may have a relatively large impact to the reserve and associated expense. Reserve for veterinary invoices Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands): Three Months Ended March 31, Subscription 2019 2018 Reserve at beginning of year $ 13,875 $ 11,059 Veterinary invoices during the period related to: Current year 53,436 45,198 Prior years 202 (61 ) Total veterinary invoice expense 53,638 45,137 Amounts paid during the period related to: Current year 42,650 36,142 Prior years 10,015 8,250 Total paid 52,665 44,392 Non-cash expenses 201 156 Reserve at end of period $ 14,647 $ 11,648 The Company's reserve for the subscription business segment increased from $13.9 million at December 31, 2018 to $14.6 million at March 31, 2019 . This change was comprised of $53.6 million in expense recorded during the period less $52.7 million in payments of veterinary invoices. The $53.6 million in veterinary invoice expense incurred included an adjustment of $0.2 million to the reserves relating to prior years, which was the result of ongoing analysis of recent payment trends. For the three months ended March 31, 2018 , the Company decreased prior year reserves by $0.1 million as a result of analysis of payment trends. Summarized below are the changes in total liability for the Company's other business segment (in thousands): Three Months Ended March 31, Other Business 2019 2018 Reserve at beginning of year $ 2,187 $ 1,697 Veterinary invoices during the period related to: Current year 7,995 5,218 Prior years (351 ) (242 ) Total veterinary invoice expense 7,644 4,976 Amounts paid during the period related to: Current year 5,856 3,734 Prior years 1,447 1,137 Total paid 7,303 4,871 Non-cash expenses — — Reserve at end of period $ 2,528 $ 1,802 The Company’s reserve for the other business segment increased from $2.2 million at December 31, 2018 to $2.5 million at March 31, 2019 . This change was comprised of $7.6 million in expense recorded during the period less $7.3 million in payments of veterinary invoices. The $7.6 million in veterinary invoice expense incurred included a reduction of $0.4 million to the reserves relating to prior years, which was the result of ongoing analysis of recent payment trends. For the three months ended March 31, 2018 , the Company decreased prior year reserves by $0.2 million as a result of analysis of payment trends. Reserve for veterinary invoices, by year of occurrence In the following tables, the reserve for veterinary invoices for each segment is presented as the amount (in thousands) by year the veterinary invoice relates to, referred to as the year of occurrence. Subscription As of March 31, 2019 Year of Occurrence 2017 and prior $ 1,042 2018 3,020 2019 10,585 $ 14,647 Other Business As of March 31, 2019 Year of Occurrence 2017 and prior $ 12 2018 377 2019 2,139 $ 2,528 |
Stock-based Compensation
Stock-based Compensation | 3 Months Ended |
Mar. 31, 2019 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | Stock-Based Compensation Stock-based compensation expense includes stock options, restricted stock awards, and restricted stock units granted to employees and non-employees and has been reported in the Company’s consolidated statements of operations depending on the function performed by the employee or non-employee. Stock-based compensation expense recognized in the consolidated statements of operations was as follows (in thousands): Three Months Ended March 31, 2019 2018 Veterinary invoice expense $ 161 $ 120 Other cost of revenue 86 77 Technology and development 63 49 General and administrative 618 449 Sales and marketing 429 273 Total stock-based compensation $ 1,357 $ 968 As of March 31, 2019 , the Company had 399,417 unvested stock options and 716,319 unvested restricted stock awards and restricted stock units that are expected to vest. Stock-based compensation expenses of $2.6 million related to unvested stock options and $16.8 million related to unvested restricted stock awards and restricted stock units are expected to be recognized over a weighted average period of approximately 1.7 years and 2.9 years, respectively. Stock Options A summary of the Company's stock option activity is as follows: Number of Options Weighted Average Exercise Price per Share Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2018 2,621,503 $ 9.01 $ 43,136 Granted — — — Exercised (105,963 ) 6.48 2,376 Forfeited (1,594 ) 15.26 — Outstanding as of March 31, 2019 2,513,946 9.11 59,401 Exercisable as of March 31, 2019 2,114,529 $ 7.74 $ 52,873 As of March 31, 2019 , stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 5.4 years and 5.0 years, respectively. Restricted Stock Awards and Restricted Stock Units A summary of the Company’s restricted stock award and restricted stock unit activity is as follows: Number of Weighted Average Unvested shares as of December 31, 2018 451,160 $ 22.16 Granted 337,279 29.89 Vested (66,903 ) 27.92 Forfeited (5,217 ) 27.99 Unvested shares as of March 31, 2019 716,319 $ 25.22 |
Leases (Notes)
Leases (Notes) | 3 Months Ended |
Mar. 31, 2019 | |
Leases [Abstract] | |
Leases of Lessor Disclosure [Text Block] | Leases The Company leases certain office space and equipment from third parties and recognizes lease expense on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on its consolidated balance sheets. The Company had $0.1 million right-of-use assets and lease liabilities for long-term operating leases as of March 31, 2019 . The Company also leases a portion of its building to third parties and records related rental income within general and administrative expense in the consolidated statements of operations. These leases have remaining initial lease terms of 2 years to 8 years, some of which give the tenants options to renew the leases for up to an additional 10 years, and options to terminate the leases after 3 years of the initial lease terms, with early termination fees required. The Company recorded rental income of $0.6 million for the three months ended March 31, 2019 . The following table summarizes the Company's future rental payments to be received from non-cancellable leases in place as of March 31, 2019 (in thousands): Year ending December 31: 2019 $ 1,603 2020 1,460 2021 1,210 2022 1,173 2023 1,210 Thereafter 3,238 Total rental payments $ 9,894 |
Stockholders' Equity (Notes)
Stockholders' Equity (Notes) | 3 Months Ended |
Mar. 31, 2019 | |
Stockholders' Equity Attributable to Parent [Abstract] | |
Stockholders' Equity Note Disclosure [Text Block] | Stockholders' Equity As of March 31, 2019 , the Company had 100,000,000 shares of common stock authorized and 34,467,465 shares of common stock outstanding. Holders of common stock are entitled to one vote on each matter properly submitted to the stockholders of the Company except those related to matters concerning possible outstanding preferred stock. At March 31, 2019 , the Company had 10,000,000 shares of undesignated shares of preferred stock authorized for future issuance and did not have any outstanding shares of preferred stock. The holders of common stock are also entitled to receive dividends as and when declared by the board of directors of the Company, whenever funds are legally available. These rights are subordinate to the dividend rights of holders of all classes of stock outstanding at the time. The Company is unable to pay dividends to stockholders as of March 31, 2019 due to restrictions in its credit agreements. In June 2018, the Company completed a follow-on public offering (the June 2018 follow-on public offering) whereby the Company sold 2,090,909 shares of common stock (inclusive of 272,727 shares of common stock sold by the Company pursuant to the full exercise of the underwriters' option to purchase additional shares) at a price to the public of $33.00 per share. The Company received aggregate net proceeds from the June 2018 follow-on public offering of $65.7 million , after deducting underwriting discounts and commissions and offering expenses payable by the Company. The proceeds were primarily used to purchase real estate consisting of properties in use as the Company's home office. In addition, in August 2018, the Company issued 303,030 shares of common stock via a private placement to an accredited investor as a portion of the purchase price of the real estate. During the three months ended March 31, 2019 , 450,000 of the Company's outstanding warrants were exercised. As of March 31, 2019 , warrants to purchase 30,000 shares of the Company's common stock at $10.00 |
Segments
Segments | 3 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
Segment Reporting Disclosure [Text Block] | Segments The Company has two segments: subscription business and other business. The subscription business segment includes monthly subscription fees related to the Company’s medical insurance which is marketed directly to consumers, while the other business segment includes all other business that is not directly marketed to consumers. The chief operating decision maker primarily uses two measures to evaluate segment GAAP financial performance: revenue and gross profit. Additionally, other operating expenses, such as sales and marketing expenses, are allocated to each segment and evaluated when material. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets. Revenue and gross profit of the Company’s segments were as follows (in thousands): Three Months Ended March 31, 2019 2018 Revenue: Subscription business $ 74,222 $ 61,517 Other business 12,756 8,243 86,978 69,760 Veterinary invoice expense: Subscription business 53,638 45,137 Other business 7,644 4,976 61,282 50,113 Other cost of revenue: Subscription business 6,749 5,877 Other business 3,915 2,706 10,664 8,583 Gross profit: Subscription business 13,835 10,503 Other business 1,197 561 15,032 11,064 Technology and development 2,669 2,164 General and administrative 5,419 4,458 Sales and marketing: Subscription business 8,097 5,851 Other business 130 87 8,227 5,938 Operating loss $ (1,283 ) $ (1,496 ) The following table presents the Company’s revenue by geographic region of the member (in thousands): Three Months Ended March 31, 2019 2018 United States $ 71,157 $ 56,009 Canada 15,821 13,751 Total revenue $ 86,978 $ 69,760 Substantially all of the Company’s long-lived assets were located in the United States as of March 31, 2019 and December 31, 2018 |
Subsequent Events (Notes)
Subsequent Events (Notes) | 3 Months Ended |
Mar. 31, 2019 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | Subsequent Events On April 29, 2019 , the Company amended its credit agreement, extending the maturity date of the revolving line of credit to June 2022, and reducing the interest rate to the greater of 4.5%, or 0.75% plus the prime rate |
Nature of Operations and Summ_2
Nature of Operations and Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Business Description and Basis of Presentation [Text Block] | Description of Business and Basis of Presentation Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the Company) provides medical insurance for cats and dogs throughout the United States, Canada and Puerto Rico. The financial data as of December 31, 2018 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income (loss), stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on February 14, 2019 (the 2018 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2018 10-K. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period. Use of Estimates |
Basis of Accounting, Policy [Policy Text Block] | The financial data as of December 31, 2018 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income (loss), stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on February 14, 2019 (the 2018 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2018 10-K. Operating results for the three months ended March 31, 2019 |
Use of Estimates [Policy Text Block] | Use of EstimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2018 10-K for additional discussion of these estimates and assumptions. |
Investment, Policy [Policy Text Block] | . |
Comprehensive Income, Policy [Policy Text Block] | . |
Income Tax, Policy [Policy Text Block] | . |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Pronouncements The Company adopted Accounting Standards Update (ASU) No. 2016-02 Leases (Topic 842), as amended, using the modified retrospective approach under which the transition provisions were applied as of January 1, 2019. In addition, the Company elected the “package of practical expedients” under the transition guidance within the new standard to not reassess prior conclusions about lease identification, lease classification, and initial direct costs for existing lease contracts. The Company also elected the practical expedient to not separate lease and non-lease components, if any, for all lease contracts. Upon adoption of this standard, the Company recorded approximately $0.1 million right-of-use assets and lease liabilities for operating leases. They were classified as other long-term assets and other liabilities on the Company's consolidated balance sheets. The standard did not have a material impact on the Company's consolidated statements of operations, stockholders' equity, or cash flows. Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued an ASU amending the measurement of credit losses on financial instruments. The ASU requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within that reporting period, with early adoption permitted. The Company is currently in the process of evaluating the impact the adoption of this ASU will have on its consolidated financial statements. |
Other Investments Investment in
Other Investments Investment in Variable Interest Entity (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Investments, All Other Investments [Abstract] | |
Variable Interest Entity Disclosure [Text Block] | Investment in Variable Interest Entity In July 2018, the Company purchased $3.0 million in preferred stock of a privately held corporation with a complementary business line. The Company does not have power over the activities that most significantly impact the economic performance of the variable interest entity and is, therefore, not the primary beneficiary. The Company's investment in preferred stock is accounted for as an available-for-sale debt security. Through January 2020, the Company has agreed to purchase an additional $4.0 million in preferred stock of the variable interest entity, contingent upon the exercise of this option by the variable interest entity. The Company has the option to purchase the variable interest entity on the fifth anniversary of the initial preferred stock purchase. Additionally, the Company has extended a $2.5 million revolving line of credit to the variable interest entity. The Company's investment and amounts loaned under the line of credit are recorded in other long-term assets on its consolidated balance sheet. Outstanding loan balance under the line of credit was $2.1 million and $0.6 million |
Other Investments Investment _2
Other Investments Investment in Joint Venture (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Investments, All Other Investments [Abstract] | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | Investment in Joint Venture In September 2018, the Company acquired a non-controlling equity interest in a joint venture, whereby it has committed to licensing certain intellectual property and contributing up to $2.2 million AUD upon the achievement of specific operational milestones over a period of at least four years from the agreement execution date. As of March 31, 2019, the Company has contributed $0.3 million |
Fair Value Notes Receivable (Po
Fair Value Notes Receivable (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Loans, Notes, Trade and Other Receivables Disclosure [Text Block] | The Company's other long-term assets balance included $4.5 million of notes receivable as of March 31, 2019 and $3.0 million of notes receivable as of December 31, 2018, recorded at its estimated collectible amount. The Company estimates that the carrying value of the note receivable approximates its fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy, and is based on market interest rates and the assessed creditworthiness of the third party. The Company estimates the fair value of its long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at March 31, 2019 and December 31, 2018 |
Fair Value Fair Value (Policies
Fair Value Fair Value (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments, Policy [Policy Text Block] | The Company measures the fair value of restricted cash, money market funds, and foreign deposits based on quoted prices in active markets for identical assets. The fair value of the municipal bond is based on either recent trades in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. The estimated fair value of the Company's investment in the variable interest entity is a Level 3 measurement, and is based on market interest rates, the assessed creditworthiness of the entity, and the estimated fair value of the entity's common stock. As of March 31, 2019 |
Claims Reserve Claims Reserve (
Claims Reserve Claims Reserve (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] | |
Liability Reserve Estimate, Policy [Policy Text Block] | Reserve for Veterinary InvoicesThe reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. The reserve estimate involves actuarial projections, and is based on management's assessment of facts and circumstances currently known, and assumptions about anticipated patterns. The reserve is made for each of the Company's segments, subscription and other business, and is continually refined as the Company receives and pays veterinary invoices. Changes in management's assumptions and estimates may have a relatively large impact to the reserve and associated expense. |
Segments Segments (Policies)
Segments Segments (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
Segment Reporting, Policy [Policy Text Block] | The Company has two segments: subscription business and other business. The subscription business segment includes monthly subscription fees related to the Company’s medical insurance which is marketed directly to consumers, while the other business segment includes all other business that is not directly marketed to consumers. The chief operating decision maker primarily uses two measures to evaluate segment GAAP financial performance: revenue and gross profit. Additionally, other operating expenses, such as sales and marketing expenses, are allocated to each segment and evaluated when material. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets. |
Net Loss per Share (Tables)
Net Loss per Share (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Earnings Per Share, Basic and Diluted [Abstract] | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | The following potentially dilutive equity securities were not included in the diluted earnings per share of common stock calculation because they would have had an antidilutive effect: Three Months Ended March 31, 2019 2018 Stock options 2,513,946 3,878,716 Restricted stock awards and restricted stock units 716,319 546,638 Warrants 30,000 510,000 |
Investment Securities Available
Investment Securities Available-for-Sale (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Investments [Abstract] | |
Investment [Table Text Block] | The amortized cost, gross unrealized holding gains and losses, and estimates of fair value of long-term and short-term investments by major security type and class of security were as follows as of March 31, 2019 and December 31, 2018 (in thousands): Amortized Gross Gross Fair As of March 31, 2019 Long-term investments: Foreign deposits $ 2,701 $ — $ — $ 2,701 Municipal bond 1,000 — — 1,000 $ 3,701 $ — $ — $ 3,701 Short-term investments: U.S. Treasury securities $ 6,660 $ — $ — $ 6,660 Certificates of deposit 438 1 — 439 U.S. government funds 54,550 — — 54,550 $ 61,648 $ 1 $ — $ 61,649 Amortized Gross Gross Fair As of December 31, 2018 Long-term investments: Foreign deposits $ 2,573 $ — $ — $ 2,573 Municipal bond 1,000 — (19 ) 981 $ 3,573 $ — $ (19 ) $ 3,554 Short-term investments: U.S. Treasury securities $ 6,645 $ — $ (3 ) $ 6,642 Certificates of deposit 437 — — 437 U.S. government funds 47,477 — — 47,477 $ 54,559 $ — $ (3 ) $ 54,556 |
Available-for-sale Securities [Table Text Block] | Maturities of debt securities classified as available-for-sale were as follows (in thousands): As of March 31, 2019 Amortized Fair Available-for-sale: Due after one year through five years $ 3,701 $ 3,701 $ 3,701 $ 3,701 |
Fair Value (Tables)
Fair Value (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Fair Value Disclosures [Abstract] | |
Fair value, asset & liabilities measured on recurring basis [Table Text Block] | The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands): As of March 31, 2019 Fair Value Level 1 Level 2 Level 3 Assets Restricted cash $ 1,400 $ 1,400 $ — $ — Money market funds 4,022 4,022 — — Fixed maturities: Foreign deposits 2,701 2,701 — — Municipal bond 1,000 — 1,000 — Investment in variable interest entity 3,000 — — 3,000 Total $ 12,123 $ 8,123 $ 1,000 $ 3,000 As of December 31, 2018 Fair Value Level 1 Level 2 Level 3 Assets Restricted cash $ 1,400 $ 1,400 $ — $ — Money market funds 2,010 2,010 — — Fixed maturities: Foreign deposits 2,573 2,573 — — Municipal bond 981 — 981 — Investment in variable interest entity 3,000 — — 3,000 Total $ 9,964 $ 5,983 $ 981 $ 3,000 The Company measures the fair value of restricted cash, money market funds, and foreign deposits based on quoted prices in active markets for identical assets. The fair value of the municipal bond is based on either recent trades in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. The estimated fair value of the Company's investment in the variable interest entity is a Level 3 measurement, and is based on market interest rates, the assessed creditworthiness of the entity, and the estimated fair value of the entity's common stock. As of March 31, 2019 |
Claims Reserve (Tables)
Claims Reserve (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] | |
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] | Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands): Three Months Ended March 31, Subscription 2019 2018 Reserve at beginning of year $ 13,875 $ 11,059 Veterinary invoices during the period related to: Current year 53,436 45,198 Prior years 202 (61 ) Total veterinary invoice expense 53,638 45,137 Amounts paid during the period related to: Current year 42,650 36,142 Prior years 10,015 8,250 Total paid 52,665 44,392 Non-cash expenses 201 156 Reserve at end of period $ 14,647 $ 11,648 The Company's reserve for the subscription business segment increased from $13.9 million at December 31, 2018 to $14.6 million at March 31, 2019 . This change was comprised of $53.6 million in expense recorded during the period less $52.7 million in payments of veterinary invoices. The $53.6 million in veterinary invoice expense incurred included an adjustment of $0.2 million to the reserves relating to prior years, which was the result of ongoing analysis of recent payment trends. For the three months ended March 31, 2018 , the Company decreased prior year reserves by $0.1 million as a result of analysis of payment trends. Summarized below are the changes in total liability for the Company's other business segment (in thousands): Three Months Ended March 31, Other Business 2019 2018 Reserve at beginning of year $ 2,187 $ 1,697 Veterinary invoices during the period related to: Current year 7,995 5,218 Prior years (351 ) (242 ) Total veterinary invoice expense 7,644 4,976 Amounts paid during the period related to: Current year 5,856 3,734 Prior years 1,447 1,137 Total paid 7,303 4,871 Non-cash expenses — — Reserve at end of period $ 2,528 $ 1,802 The Company’s reserve for the other business segment increased from $2.2 million at December 31, 2018 to $2.5 million at March 31, 2019 . This change was comprised of $7.6 million in expense recorded during the period less $7.3 million in payments of veterinary invoices. The $7.6 million in veterinary invoice expense incurred included a reduction of $0.4 million to the reserves relating to prior years, which was the result of ongoing analysis of recent payment trends. For the three months ended March 31, 2018 , the Company decreased prior year reserves by $0.2 million |
IBRN plus expected development on reported claims[Table Text Block] | In the following tables, the reserve for veterinary invoices for each segment is presented as the amount (in thousands) by year the veterinary invoice relates to, referred to as the year of occurrence. Subscription As of March 31, 2019 Year of Occurrence 2017 and prior $ 1,042 2018 3,020 2019 10,585 $ 14,647 Other Business As of March 31, 2019 Year of Occurrence 2017 and prior $ 12 2018 377 2019 2,139 $ 2,528 |
Stock-based Compensation (Table
Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Stock-based compensation expense includes stock options, restricted stock awards, and restricted stock units granted to employees and non-employees and has been reported in the Company’s consolidated statements of operations depending on the function performed by the employee or non-employee. Stock-based compensation expense recognized in the consolidated statements of operations was as follows (in thousands): Three Months Ended March 31, 2019 2018 Veterinary invoice expense $ 161 $ 120 Other cost of revenue 86 77 Technology and development 63 49 General and administrative 618 449 Sales and marketing 429 273 Total stock-based compensation $ 1,357 $ 968 As of March 31, 2019 , the Company had 399,417 unvested stock options and 716,319 unvested restricted stock awards and restricted stock units that are expected to vest. Stock-based compensation expenses of $2.6 million related to unvested stock options and $16.8 million related to unvested restricted stock awards and restricted stock units are expected to be recognized over a weighted average period of approximately 1.7 years and 2.9 |
Share-based Compensation, Stock Options, Activity [Table Text Block] | A summary of the Company's stock option activity is as follows: Number of Options Weighted Average Exercise Price per Share Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2018 2,621,503 $ 9.01 $ 43,136 Granted — — — Exercised (105,963 ) 6.48 2,376 Forfeited (1,594 ) 15.26 — Outstanding as of March 31, 2019 2,513,946 9.11 59,401 Exercisable as of March 31, 2019 2,114,529 $ 7.74 $ 52,873 As of March 31, 2019 , stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 5.4 years and 5.0 |
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] | A summary of the Company’s restricted stock award and restricted stock unit activity is as follows: Number of Weighted Average Unvested shares as of December 31, 2018 451,160 $ 22.16 Granted 337,279 29.89 Vested (66,903 ) 27.92 Forfeited (5,217 ) 27.99 Unvested shares as of March 31, 2019 716,319 $ 25.22 |
Stock-based Compensation Stockh
Stock-based Compensation Stockholder's Equity (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Class of Warrant or Right [Line Items] | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | During the three months ended March 31, 2019 , 450,000 of the Company's outstanding warrants were exercised. As of March 31, 2019 , warrants to purchase 30,000 shares of the Company's common stock at $10.00 |
Stock-based Compensation Follow
Stock-based Compensation Follow-on Public Offering (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Equity [Abstract] | |
Follow-on Public Offering, June 2018 [Table Text Block] | In June 2018, the Company completed a follow-on public offering (the June 2018 follow-on public offering) whereby the Company sold 2,090,909 shares of common stock (inclusive of 272,727 shares of common stock sold by the Company pursuant to the full exercise of the underwriters' option to purchase additional shares) at a price to the public of $33.00 per share. The Company received aggregate net proceeds from the June 2018 follow-on public offering of $65.7 million , after deducting underwriting discounts and commissions and offering expenses payable by the Company. The proceeds were primarily used to purchase real estate consisting of properties in use as the Company's home office. In addition, in August 2018, the Company issued 303,030 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Stockholders' Equity Attributable to Parent [Abstract] | |
Follow-on Public Offering, June 2018 [Table Text Block] | In June 2018, the Company completed a follow-on public offering (the June 2018 follow-on public offering) whereby the Company sold 2,090,909 shares of common stock (inclusive of 272,727 shares of common stock sold by the Company pursuant to the full exercise of the underwriters' option to purchase additional shares) at a price to the public of $33.00 per share. The Company received aggregate net proceeds from the June 2018 follow-on public offering of $65.7 million , after deducting underwriting discounts and commissions and offering expenses payable by the Company. The proceeds were primarily used to purchase real estate consisting of properties in use as the Company's home office. In addition, in August 2018, the Company issued 303,030 |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | During the three months ended March 31, 2019 , 450,000 of the Company's outstanding warrants were exercised. As of March 31, 2019 , warrants to purchase 30,000 shares of the Company's common stock at $10.00 |
Segments (Tables)
Segments (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
Revenue and Gross Profit from Segments [Table Text Block] | Revenue and gross profit of the Company’s segments were as follows (in thousands): Three Months Ended March 31, 2019 2018 Revenue: Subscription business $ 74,222 $ 61,517 Other business 12,756 8,243 86,978 69,760 Veterinary invoice expense: Subscription business 53,638 45,137 Other business 7,644 4,976 61,282 50,113 Other cost of revenue: Subscription business 6,749 5,877 Other business 3,915 2,706 10,664 8,583 Gross profit: Subscription business 13,835 10,503 Other business 1,197 561 15,032 11,064 Technology and development 2,669 2,164 General and administrative 5,419 4,458 Sales and marketing: Subscription business 8,097 5,851 Other business 130 87 8,227 5,938 Operating loss $ (1,283 ) $ (1,496 ) |
Revenue from External Customers by Geographic Areas [Table Text Block] | The following table presents the Company’s revenue by geographic region of the member (in thousands): Three Months Ended March 31, 2019 2018 United States $ 71,157 $ 56,009 Canada 15,821 13,751 Total revenue $ 86,978 $ 69,760 |
Nature of Operations and Summ_3
Nature of Operations and Summary of Significant Accounting Policies (Details) Narrative $ in Millions | Mar. 31, 2019USD ($) |
Organization and Basis of Presentation [Line Items] | |
Operating Lease, Right-of-Use Asset | $ 0.1 |
Net Loss per Share (Details) Sc
Net Loss per Share (Details) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Employee Stock Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 2,513,946 | 3,878,716 |
Restricted Stock Units (RSUs) [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 716,319 | 546,638 |
Warrant [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 30,000 | 510,000 |
Net Loss per Share Computation
Net Loss per Share Computation of Net Income (Loss) Per Share (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Schedule of Earnings Per Share, Basic and Diluted [Line Items] | ||
Net Income (Loss) Available to Common Stockholders, Basic | $ (1,296) | $ (1,480) |
Investment Securities (Details)
Investment Securities (Details) Investment Schedule - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Investment [Line Items] | ||
Available-for-sale securities, amortized cost | $ 3,701 | |
Available-for-sale Securities, Gross Unrealized Gain | 0 | $ 0 |
Available-for-sale Securities, Gross Unrealized Loss | 0 | (19) |
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Amortized Cost Basis | 3,701 | 3,573 |
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 3,701 | 3,554 |
Short-term investments, amortized cost | 61,648 | 54,559 |
Short-term Investments, Gross Unrealized Holding Gains | 1 | 0 |
Short-term investments, gross unrealized holding losses | 0 | (3) |
Short-term Investments, fair value | 61,649 | 54,556 |
Deposits [Member] | ||
Investment [Line Items] | ||
Available-for-sale securities, amortized cost | 2,701 | 2,573 |
Available-for-sale Securities, Gross Unrealized Gain | 0 | 0 |
Available-for-sale Securities, Gross Unrealized Loss | 0 | 0 |
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 2,701 | 2,573 |
Municipal Bonds [Member] | ||
Investment [Line Items] | ||
Available-for-sale securities, amortized cost | 1,000 | 1,000 |
Available-for-sale Securities, Gross Unrealized Gain | 0 | 0 |
Available-for-sale Securities, Gross Unrealized Loss | 0 | (19) |
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 1,000 | 981 |
U.S. Treasury securities | ||
Investment [Line Items] | ||
Short-term investments, amortized cost | 6,660 | 6,645 |
Short-term Investments, Gross Unrealized Holding Gains | 0 | 0 |
Short-term investments, gross unrealized holding losses | 0 | (3) |
Short-term Investments, fair value | 6,660 | 6,642 |
Certificates of deposit | ||
Investment [Line Items] | ||
Short-term investments, amortized cost | 438 | 437 |
Short-term Investments, Gross Unrealized Holding Gains | 1 | 0 |
Short-term investments, gross unrealized holding losses | 0 | 0 |
Short-term Investments, fair value | 439 | 437 |
US government debt securities | ||
Investment [Line Items] | ||
Short-term investments, amortized cost | 54,550 | 47,477 |
Short-term Investments, Gross Unrealized Holding Gains | 0 | 0 |
Short-term investments, gross unrealized holding losses | 0 | 0 |
Short-term Investments, fair value | $ 54,550 | $ 47,477 |
Investment Securities (Detail_2
Investment Securities (Details) Available-for-Sale - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Available-for-sale Securities [Abstract] | ||
Available-for-sale securities, debt maturities, year two through five, amortized cost basis | $ 3,701 | |
Available-for-sale securities, debt maturities, year two through five, fair value | 3,701 | |
Available-for-sale securities, amortized cost | 3,701 | $ 3,573 |
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | $ 3,701 | $ 3,554 |
Other Investments (Details)
Other Investments (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended |
Mar. 31, 2019 | Dec. 31, 2018 | |
Investments, All Other Investments [Abstract] | ||
Purchase of Equity Interest | $ 3 | |
Other Commitment | 2.2 | |
Investment Company, Committed Capital | 4 | |
Increase (Decrease) in Notes Receivables | 2.5 | |
Line of Credit outstanding balance, Variable Interest Entity | 2.1 | $ 0.6 |
Payments to Acquire Interest in Joint Venture | $ 0.3 |
Fair Value (Details) Unobservab
Fair Value (Details) Unobservable - USD ($) | Mar. 31, 2019 | Dec. 31, 2018 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Restricted Cash | $ 1,400,000 | $ 1,400,000 |
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 3,701,000 | 3,554,000 |
Noncontrolling Interest in Variable Interest Entity | 3,000,000 | 3,000,000 |
Assets, Fair Value Disclosure | 12,123,000 | 9,964,000 |
Notes Receivable, Fair Value Disclosure | 4,500,000 | 3,000,000 |
Fair Value, Inputs, Level 1 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Noncontrolling Interest in Variable Interest Entity | 0 | 0 |
Assets, Fair Value Disclosure | 8,123,000 | 5,983,000 |
Fair Value, Inputs, Level 2 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Noncontrolling Interest in Variable Interest Entity | 0 | 0 |
Assets, Fair Value Disclosure | 1,000,000 | 981,000 |
Fair Value, Inputs, Level 3 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Noncontrolling Interest in Variable Interest Entity | 3,000,000 | 3,000,000 |
Assets, Fair Value Disclosure | 3,000,000 | 3,000,000 |
Cash and Cash Equivalents [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Restricted Cash | 1,400,000 | 1,400,000 |
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Restricted Cash | 1,400,000 | 1,400,000 |
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Restricted Cash | 0 | 0 |
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Restricted Cash | 0 | 0 |
Deposits [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 2,701,000 | 2,573,000 |
Cash and Cash Equivalents, Fair Value Disclosure | 4,022,000 | 2,010,000 |
Deposits [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 2,701,000 | 2,573,000 |
Cash and Cash Equivalents, Fair Value Disclosure | 4,022,000 | 2,010,000 |
Deposits [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 0 | 0 |
Cash and Cash Equivalents, Fair Value Disclosure | 0 | 0 |
Deposits [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 0 | 0 |
Cash and Cash Equivalents, Fair Value Disclosure | 0 | 0 |
Municipal bond | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 1,000,000 | 981,000 |
Available-for-sale Securities, Debt Maturities, Single Maturity Date | 1,000,000 | 981,000 |
Municipal bond | Fair Value, Inputs, Level 1 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale Securities, Debt Maturities, Single Maturity Date | 0 | 0 |
Municipal bond | Fair Value, Inputs, Level 2 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale Securities, Debt Maturities, Single Maturity Date | 1,000,000 | 981,000 |
Municipal bond | Fair Value, Inputs, Level 3 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale Securities, Debt Maturities, Single Maturity Date | $ 0 | $ 0 |
Fair Value (Details) Narrative
Fair Value (Details) Narrative - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Note Receivable, Fair Value [Abstract] | ||
Notes Receivable, Fair Value Disclosure | $ 4.5 | $ 3 |
Debt (Details) Narrative
Debt (Details) Narrative $ in Millions | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Debt Disclosure [Abstract] | |
Line of Credit Facility, Maximum Borrowing Capacity | $ 50 |
Line of credit facility, interest rate description | greater of 4.5%, or 1.25% plus the prime rate |
Line of Credit Facility, Interest Rate During Period | 6.75% |
Line of Credit Facility, Ancillary Services and Letter of Credit | $ 4.5 |
Restricted Cash and Cash Equivalents | 1.4 |
Line of Credit Facility, Remaining Borrowing Capacity | 31.4 |
Line of Credit Facility, Ancillary Services and Letter of Credit | 0.4 |
Long-term Line of Credit | 18.2 |
Line of Credit Financing Fee | $ 0.1 |
Commitment and Contingencies Ob
Commitment and Contingencies Obligation for VIE (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Commitments and Contingencies Disclosure [Abstract] | |
Investment Company, Committed Capital | $ 4 |
Claims Reserve (Details) Claims
Claims Reserve (Details) Claims Loss Roll-forward - Other business - USD ($) $ in Thousands | 3 Months Ended | |||
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | |
Supplementary Insurance Information, by Segment [Line Items] | ||||
Claims Reserve | $ 2,528 | $ 1,802 | $ 2,187 | $ 1,697 |
Current Year Claims Incurred | 7,995 | 5,218 | ||
Prior Year Claims Incurred | (351) | (242) | ||
Total Claims Incurred | 7,644 | 4,976 | ||
Current Year Claims Paid | 5,856 | 3,734 | ||
Prior Years Claims Paid | 1,447 | 1,137 | ||
Total Claims Paid | 7,303 | 4,871 | ||
Claims expense non-cash | 0 | $ 0 | ||
Claims Reserve by Loss Year | ||||
Incurred but Not Reported (IBNR) Claims Liability | 2,528 | |||
Short-duration Insurance Contracts, Accident Year 2017 [Member] | ||||
Claims Reserve by Loss Year | ||||
Incurred but Not Reported (IBNR) Claims Liability | 12 | |||
Shortduration insurance contracts for accident year 2018 [Member] | ||||
Claims Reserve by Loss Year | ||||
Incurred but Not Reported (IBNR) Claims Liability | 377 | |||
Short-duration Insurance Contracts, Accident Year 2019 [Member] | ||||
Claims Reserve by Loss Year | ||||
Incurred but Not Reported (IBNR) Claims Liability | $ 2,139 |
Claims Reserve (Details) Narrat
Claims Reserve (Details) Narrative - USD ($) $ in Thousands | 3 Months Ended | |||
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | |
Subscription business | ||||
Supplementary Insurance Information, by Segment [Line Items] | ||||
Claims Reserve | $ 14,647 | $ 11,648 | $ 13,875 | $ 11,059 |
Total Claims Incurred | 53,638 | 45,137 | ||
Total Claims Paid | 52,665 | 44,392 | ||
Prior Year Claims Incurred | 202 | (61) | ||
Other business | ||||
Supplementary Insurance Information, by Segment [Line Items] | ||||
Claims Reserve | 2,528 | 1,802 | $ 2,187 | $ 1,697 |
Total Claims Incurred | 7,644 | 4,976 | ||
Total Claims Paid | 7,303 | 4,871 | ||
Prior Year Claims Incurred | $ (351) | $ (242) |
Claims Reserve Claims Reserve_2
Claims Reserve Claims Reserve (Details) - USD ($) $ in Thousands | 3 Months Ended | |||
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | |
Subscription business | ||||
Liability for Claims and Claims Adjustment Expense [Line Items] | ||||
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net | $ 14,647 | |||
Claims Reserve | 14,647 | $ 11,648 | $ 13,875 | $ 11,059 |
Current Year Claims Incurred | 53,436 | 45,198 | ||
Prior Year Claims Incurred | 202 | (61) | ||
Current Year Claims Paid | 42,650 | 36,142 | ||
Prior Years Claims Paid | 10,015 | 8,250 | ||
Total Claims Paid | 52,665 | 44,392 | ||
Claims expense non-cash | 201 | 156 | ||
Total Claims Incurred | 53,638 | 45,137 | ||
Other business | ||||
Liability for Claims and Claims Adjustment Expense [Line Items] | ||||
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net | 2,528 | |||
Claims Reserve | 2,528 | 1,802 | $ 2,187 | $ 1,697 |
Current Year Claims Incurred | 7,995 | 5,218 | ||
Prior Year Claims Incurred | (351) | (242) | ||
Current Year Claims Paid | 5,856 | 3,734 | ||
Prior Years Claims Paid | 1,447 | 1,137 | ||
Total Claims Paid | 7,303 | 4,871 | ||
Claims expense non-cash | 0 | 0 | ||
Total Claims Incurred | 7,644 | $ 4,976 | ||
Short-duration Insurance Contracts, Accident Year 2017 [Member] | Subscription business | ||||
Liability for Claims and Claims Adjustment Expense [Line Items] | ||||
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net | 1,042 | |||
Short-duration Insurance Contracts, Accident Year 2017 [Member] | Other business | ||||
Liability for Claims and Claims Adjustment Expense [Line Items] | ||||
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net | 12 | |||
Shortduration insurance contracts for accident year 2018 [Member] | Subscription business | ||||
Liability for Claims and Claims Adjustment Expense [Line Items] | ||||
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net | 3,020 | |||
Shortduration insurance contracts for accident year 2018 [Member] | Other business | ||||
Liability for Claims and Claims Adjustment Expense [Line Items] | ||||
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net | 377 | |||
Short-duration Insurance Contracts, Accident Year 2019 [Member] | Subscription business | ||||
Liability for Claims and Claims Adjustment Expense [Line Items] | ||||
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net | 10,585 | |||
Short-duration Insurance Contracts, Accident Year 2019 [Member] | Other business | ||||
Liability for Claims and Claims Adjustment Expense [Line Items] | ||||
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net | $ 2,139 |
Stock-based Compensation (Detai
Stock-based Compensation (Details) Expense Category - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Stock-based Compensation | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | $ 1,357 | $ 968 |
Claims expense | ||
Stock-based Compensation | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | 161 | 120 |
Other Cost of Revenue | ||
Stock-based Compensation | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | 86 | 77 |
Technology and development | ||
Stock-based Compensation | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | 63 | 49 |
General and administrative | ||
Stock-based Compensation | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | 618 | 449 |
Sales and marketing | ||
Stock-based Compensation | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | $ 429 | $ 273 |
Restricted Stock Units (RSUs) [Member] | ||
Stock-based Compensation | ||
Employee share-based compensation arrangement and non-employee, weighted average remaining vesting period | 2 years 10 months 24 days | |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 16,800 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | 716,319 | |
Employee Stock Option [Member] | ||
Stock-based Compensation | ||
Employee share-based compensation arrangement and non-employee, weighted average remaining vesting period | 1 year 8 months 12 days | |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 2,600 | |
Employee share-based compensation arrangement by share-based payment award, options, nonvested, number of shares | 399,417 |
Stock-based Compensation (Det_2
Stock-based Compensation (Details) Options Granted, Exercised and Forfeited - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Dec. 31, 2018 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||
Stock-based compensation, options, outstanding, number of shares | 2,513,946 | 2,621,503 |
Stock-based compensation, options, granted, number of options | 0 | |
Stock-based compensation, options, exercised | (105,963) | |
Stock-based compensation, options, forfeited | (1,594) | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | 2,114,529 | |
Stock-based compensation, options, outstanding, weighted-average exercise price | $ 9.11 | $ 9.01 |
Stock-based compensation, options, granted, weighted-average exercise price | 0 | |
Stock-based compensation, options, exercised, weighted-average exercise price | 6.48 | |
Stock-based compensation, options, forfeited, weighted-average exercise price | 15.26 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ 7.74 | |
Stock-based compensation, options, outstanding, aggregate intrinsic value | $ 59,401 | $ 43,136 |
Stock-based compensation, options, exercised, aggregate intrinsic value | 2,376 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | $ 52,873 | |
Remaining contractual life, share-based payments, weighted average | 5 years 4 months 24 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term | 5 years |
Stock-based Compensation Restri
Stock-based Compensation Restricted Stock Awards (Details) - Restricted Stock [Member] - $ / shares | 3 Months Ended | |
Mar. 31, 2019 | Dec. 31, 2018 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | 716,319 | 451,160 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 337,279 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | (5,217) | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period | (66,903) | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Roll Forward] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | $ 25.22 | $ 22.16 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | 29.89 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | 27.99 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value | $ 27.92 |
Stock-based Compensation Stoc_2
Stock-based Compensation Stockholder Equity (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 12 Months Ended |
Mar. 31, 2019 | Dec. 31, 2018 | |
Stockholders' Equity Attributable to Parent [Abstract] | ||
Stock Issued During Period, Shares, New Issues | 2,090,909 | |
Redemption of warrants | 450,000 | |
Class of Warrant or Right, Outstanding | 30,000 | |
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 10 | |
Common Stock, Shares, Issued to Underwriter | 272,727 | |
Shares Issued, Price Per Share | $ 33 | |
Proceeds from Issuance or Sale of Equity | $ 65.7 | |
Common Stock, Shares, Issued via Private Placement | 303,030 |
Leases (Details)
Leases (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Leases [Abstract] | |
Operating Lease, Right-of-Use Asset | $ 100 |
Proceeds from Rents Received | 600 |
Operating Leases, Future Minimum Payments Receivable, Current | 1,603 |
Operating Leases, Future Minimum Payments Receivable, in Two Years | 1,460 |
Operating Leases, Future Minimum Payments Receivable, in Three Years | 1,210 |
Operating Leases, Future Minimum Payments Receivable, in Four Years | 1,173 |
Operating Leases, Future Minimum Payments Receivable, in Five Years | 1,210 |
Operating Leases, Future Minimum Payments Receivable, Thereafter | 3,238 |
Operating Leases, Future Minimum Payments Receivable | $ 9,894 |
Stockholders' Equity (Details)
Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Stockholders' Equity Attributable to Parent [Abstract] | |||
Common Stock, Shares Authorized | 100,000,000 | 100,000,000 | |
Common Stock, Shares, Outstanding | 34,467,465 | 34,025,136 | 30,121,496 |
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 | |
Stock Issued During Period, Shares, New Issues | 2,090,909 | ||
Common Stock, Shares, Issued to Underwriter | 272,727 | ||
Shares Issued, Price Per Share | $ 33 | ||
Proceeds from Issuance or Sale of Equity | $ 65.7 | ||
Common Stock, Shares, Issued via Private Placement | 303,030 | ||
Redemption of warrants | 450,000 | ||
Class of Warrant or Right, Outstanding | 30,000 | ||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 10 |
Segments (Details) Business Seg
Segments (Details) Business Segment - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Segment Reporting Information [Line Items] | ||
Revenue | $ 86,978 | $ 69,760 |
Veterinary invoice expense | 61,282 | 50,113 |
Other cost of revenue | 10,664 | 8,583 |
Gross profit | 15,032 | 11,064 |
Sales and marketing | 8,227 | 5,938 |
Technology and Development | 2,669 | 2,164 |
General and administrative | 5,419 | 4,458 |
Operating loss | (1,283) | (1,496) |
Subscription business | ||
Segment Reporting Information [Line Items] | ||
Revenue | 74,222 | 61,517 |
Veterinary invoice expense | 53,638 | 45,137 |
Other cost of revenue | 6,749 | 5,877 |
Gross profit | 13,835 | 10,503 |
Sales and marketing | 8,097 | 5,851 |
Other business | ||
Segment Reporting Information [Line Items] | ||
Revenue | 12,756 | 8,243 |
Veterinary invoice expense | 7,644 | 4,976 |
Other cost of revenue | 3,915 | 2,706 |
Gross profit | 1,197 | 561 |
Sales and marketing | $ 130 | $ 87 |
Segments (Details) Revenue by G
Segments (Details) Revenue by Geography - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Segment Reporting Information [Line Items] | ||
Revenues | $ 86,978 | $ 69,760 |
CANADA | ||
Segment Reporting Information [Line Items] | ||
Revenues | 15,821 | 13,751 |
UNITED STATES | ||
Segment Reporting Information [Line Items] | ||
Revenues | $ 71,157 | $ 56,009 |
Subsequent Events (Details)
Subsequent Events (Details) | Apr. 29, 2019 | Mar. 31, 2019 |
Subsequent Event [Line Items] | ||
Line of Credit Facility, Interest Rate Description | greater of 4.5%, or 1.25% plus the prime rate | |
Subsequent Event [Member] | ||
Subsequent Event [Line Items] | ||
Subsequent Event, Date | Apr. 29, 2019 | |
Line of Credit Facility, Interest Rate Description | greater of 4.5%, or 0.75% plus the prime rate |